Drugmaker Eli Lilly said on Feb. 26 the U.S. government agreed to buy at least 100,000 doses of the company’s newly authorized COVID-19 dual antibody cocktail for $210 million, with doses to be delivered through March-end.

Europe’s drug regulator is evaluating South Korean drugmaker Celltrion’s Covid-19 antibody treatment, the third such drug against the disease to go under real-time review in the region.

Eli Lilly will gain exclusive worldwide license to Rigel Pharmaceuticals Inc.’s autoimmune and inflammatory diseases treatment, including the company’s lead candidate R552, for potentially up to $960 million.

As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.

The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) to a combination of Eli Lilly and AbCellera’s monoclonal antibody bamlanivimab and the Lilly antibody etesevimab for mild to moderate Covid-19.

Anat Ashkenazi was tapped to take over as chief financial officer of Eli Lilly following the abrupt resignation of Josh Smiley, who departed the company following allegations of an inappropriate relationship with an employee.

Laboratory testing found that Regeneron Pharmaceuticals Inc.’s Covid-19 antibody cocktail can combat a coronavirus variant first found in South Africa, but a similar drug from Eli Lilly and Co. is inactive against it, according to a study.

Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir’s investigational monoclonal antibody VIR-7831 in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate Covid-19.

Eli Lilly and Co. will move a new Covid-19 antibody therapy to human trials targeting a coronavirus variant that was first found in South Africa, the U.S. drugmaker said.

Eli Lilly and Co.’s combination antibody drug helped reduce the risk of hospitalization and death in Covid-19 patients by 70%, the drugmaker said, citing early data from a late-stage study.